Mytrex Health Technologies, Inc.(TW:4431)
NT$20.85+-0.45 (+0.72%)
TW:4431
Mytrex Health Technologies, Inc. financials statements
NT$20.85
At close:+-0.45 (+0.72%)
Mytrex Health Technologies, Inc. (4431) Ratios
Mytrex Health Technologies, Inc. Ratios
TW:4431's free cash flow for Q2 2026 was NT$53.21M. For the 2026 fiscal year, TW:4431's free cash flow was decreased by NT$-2.19M and operating cash flow was NT$55.40M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.58 | 1.71 | 1.52 | 2.40 | 8.01 |
| Quick Ratio | 1.17 | 1.21 | 1.06 | 1.88 | 7.28 |
| Cash Ratio | 0.59 | 0.68 | 0.49 | 1.36 | 6.29 |
| Solvency Ratio | 0.04 | 0.02 | 0.07 | 0.03 | 0.31 |
| Operating Cash Flow Ratio | 0.39 | 0.08 | -0.01 | 0.20 | 0.18 |
| Short-Term Operating Cash Flow Coverage | 2.05 | 0.47 | -0.03 | 0.53 | 5.60 |
| Net Current Asset Value | NT$ 215.49M | NT$ 155.26M | NT$ 91.22M | NT$ 337.06M | NT$ 481.53M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.14 | 0.20 | 0.26 | 0.22 | 0.06 |
| Debt-to-Equity Ratio | 0.28 | 0.38 | 0.48 | 0.34 | 0.07 |
| Debt-to-Capital Ratio | 0.22 | 0.27 | 0.33 | 0.26 | 0.06 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.02 | 1.91 | 1.86 | 1.54 | 1.14 |
| Debt Service Coverage Ratio | 0.03 | 0.23 | 0.31 | 0.30 | 8.79 |
| Interest Coverage Ratio | -6.02 | -12.51 | -12.50 | -9.90 | -9.81 |
| Debt to Market Cap | 0.15 | 0.08 | 0.12 | 0.15 | 0.00 |
| Interest Debt Per Share | 4.62 | 6.37 | 9.11 | 9.22 | 1.60 |
| Net Debt to EBITDA | -19.31 | -2.81 | 2.39 | -3.11 | -11.79 |
| Profitability Margins | |||||
| Gross Profit Margin | 11.25% | 12.60% | 14.88% | 16.27% | 13.76% |
| EBIT Margin | -1.57% | -4.45% | -4.01% | -3.85% | -5.30% |
| EBITDA Margin | 0.37% | 0.98% | 3.49% | 3.39% | 12.05% |
| Operating Profit Margin | -1.57% | -4.37% | -6.03% | -3.53% | -5.30% |
| Pretax Profit Margin | -1.11% | -4.79% | -4.42% | -4.20% | -4.66% |
| Net Profit Margin | -0.85% | -4.68% | -4.35% | -6.25% | -4.80% |
| Continuous Operations Profit Margin | -1.33% | -4.82% | -4.51% | -4.69% | -4.82% |
| Net Income Per EBT | 77.22% | 97.69% | 98.32% | 148.57% | 103.04% |
| EBT Per EBIT | 70.19% | 109.70% | 73.31% | 119.22% | 87.96% |
| Return on Assets (ROA) | -1.40% | -7.19% | -4.47% | -6.18% | -1.47% |
| Return on Equity (ROE) | -2.84% | -13.73% | -8.33% | -9.53% | -1.68% |
| Return on Capital Employed (ROCE) | -4.57% | -10.38% | -9.55% | -4.59% | -1.76% |
| Return on Invested Capital (ROIC) | -3.99% | -9.00% | -7.63% | -3.94% | -1.73% |
| Return on Tangible Assets | -1.51% | -7.76% | -4.79% | -6.57% | -1.47% |
| Earnings Yield | -2.60% | -8.98% | -4.81% | -10.02% | -1.40% |
| Efficiency Ratios | |||||
| Receivables Turnover | 12.17 | 9.21 | 7.85 | 8.99 | 5.31 |
| Payables Turnover | 5.10 | 7.45 | 7.21 | 15.07 | 74.73 |
| Inventory Turnover | 8.19 | 7.65 | 5.42 | 6.68 | 4.58 |
| Fixed Asset Turnover | 23.72 | 13.63 | 5.36 | 5.16 | 1.15 |
| Asset Turnover | 1.64 | 1.54 | 1.03 | 0.99 | 0.31 |
| Working Capital Turnover Ratio | 6.63 | 6.81 | 3.54 | 2.87 | 0.48 |
| Cash Conversion Cycle | 2.98 | 38.37 | 63.23 | 71.05 | 143.52 |
| Days of Sales Outstanding | 29.99 | 39.65 | 46.49 | 40.59 | 68.73 |
| Days of Inventory Outstanding | 44.59 | 47.72 | 67.39 | 54.68 | 79.67 |
| Days of Payables Outstanding | 71.59 | 49.00 | 50.65 | 24.21 | 4.88 |
| Operating Cycle | 74.57 | 87.37 | 113.88 | 95.27 | 148.40 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 5.44 | 0.87 | -0.12 | 1.98 | 0.36 |
| Free Cash Flow Per Share | 5.33 | 0.45 | -0.80 | 0.80 | -0.47 |
| Dividend Paid and CapEx Coverage Ratio | 46.33 | 2.10 | -0.17 | 1.67 | 0.09 |
| Capital Expenditure Coverage Ratio | 46.33 | 2.10 | -0.17 | 1.67 | 0.44 |
| Operating Cash Flow Coverage Ratio | 1.22 | 0.14 | -0.01 | 0.22 | 0.23 |
| Operating Cash Flow to Sales Ratio | 0.10 | 0.02 | -0.00 | 0.05 | 0.05 |
| Free Cash Flow Yield | 30.78% | 1.81% | -2.51% | 3.18% | -1.70% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -38.44 | -11.16 | -20.78 | -9.96 | -72.24 |
| Price-to-Sales (P/S) Ratio | 0.33 | 0.52 | 0.90 | 0.62 | 3.44 |
| Price-to-Book (P/B) Ratio | 1.09 | 1.53 | 1.73 | 0.95 | 1.20 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 3.25 | 55.28 | -39.91 | 31.44 | -58.83 |
| Price-to-Operating Cash Flow Ratio | 3.18 | 28.99 | -274.54 | 12.65 | 75.48 |
| Price-to-Earnings Growth (PEG) Ratio | 0.48 | -0.24 | 0.53 | -0.02 | 0.70 |
| Enterprise Value Multiple | 69.69 | 50.21 | 28.29 | 15.27 | 16.75 |
| Enterprise Value | 499.74M | 868.50M | 1.28B | 762.06M | 588.55M |
| EV to EBITDA | 69.69 | 50.21 | 28.29 | 15.27 | 16.75 |
| EV to Sales | 0.26 | 0.49 | 0.99 | 0.52 | 2.02 |
| EV to Free Cash Flow | 2.54 | 52.35 | -43.59 | 26.13 | -34.52 |
| EV to Operating Cash Flow | 2.49 | 27.46 | -299.85 | 10.51 | 44.30 |
| Tangible Book Value Per Share | 13.63 | 14.38 | 16.24 | 24.05 | 22.84 |
| Shareholders’ Equity Per Share | 15.86 | 16.43 | 18.49 | 26.40 | 22.82 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.20 | -0.01 | -0.02 | -0.11 | -0.03 |
| Revenue Per Share | 52.72 | 48.14 | 35.42 | 40.28 | 7.98 |
| Net Income Per Share | -0.45 | -2.25 | -1.54 | -2.52 | -0.38 |
| Tax Burden | 0.77 | 0.98 | 0.98 | 1.49 | 1.03 |
| Interest Burden | 0.70 | 1.08 | 1.10 | 1.09 | 0.88 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| SG&A to Revenue | 0.13 | 0.19 | 0.23 | 0.21 | 0.18 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Income Quality | -12.10 | -0.38 | 0.07 | -1.17 | -0.95 |
Currency in TWD
